1. |
Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: what, why, and how. BMJ, 2009, 338: b375.
|
2. |
唐少文, 张渊, 陶必林, 等. 偏倚风险评估系列: (七)预后因素研究. 中华流行病学杂志, 2018, 39(7): 1003-1008.
|
3. |
陈香萍, 张奕, 庄一渝, 等. PROBAST: 诊断或预后多因素预测模型研究偏倚风险的评估工具. 中国循证医学杂志, 2020, 20(6): 737-744.
|
4. |
Deawjaroen K, Sillabutra J, Poolsup N, et al. Clinical usefulness of prediction tools to identify adult hospitalized patients at risk of drug-related problems: a systematic review of clinical prediction models and risk assessment tools. Br J Clin Pharmacol, 2022, 88(4): 1613-1629.
|
5. |
Reynolds JC, Issa MS, C Nicholson T, et al. Prognostication with point-of-care echocardiography during cardiac arrest: a systematic review. Resuscitation, 2020, 152: 56-68.
|
6. |
Lee J, Mulder F, Leeflang M, et al. QUAPAS: an adaptation of the QUADAS-2 tool to assess prognostic accuracy studies. Ann Intern Med, 2022, 175(7): 1010-1018.
|
7. |
Moons KGM, Wolff RF, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med, 2019, 170(1): W1-W33.
|
8. |
邓建新, 单路宝, 贺德强, 等. 缺失数据的处理方法及其发展趋势. 统计与决策, 2019, 35(23): 28-34.
|
9. |
Donoghoe MW, Gebski V. The importance of censoring in competing risks analysis of the subdistribution hazard. BMC Med Res Methodol, 2017, 17(1): 52.
|
10. |
Staffa SJ, Zurakowski D. Competing risks analysis of time-to-event data for cardiovascular surgeons. J Thorac Cardiovasc Surg, 2020, 159(6): 2459-2466.
|
11. |
Valenta Z, Skrabaka D, Owczarek AJ, et al. Kidney graft failure and patient survival modelling based on competing risks under nonproportional hazards. Transplant Proc, 2022, 54(4): 940-947.
|
12. |
Li C, Li J, Huang Q, et al. Developing and validating a novel nomogram used a competing-risks model for predicting the prognosis of primary fallopian tube carcinoma: a retrospective study based on the SEER database. Ann Transl Med, 2021, 9(5): 378.
|
13. |
Hagström H, Nasr P, Ekstedt M, et al. Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019, 17(6): 1148-1156.
|
14. |
Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ, 2015, 350: g7594.
|
15. |
Sauerbrei W, Taube SE, McShane LM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst, 2018, 110(8): 803-811.
|